ProCE Banner Activity

CE / CME

Honing Treatment Strategies in Advanced Prostate Cancer: Latest Evidence to Guide Clinical Practice

Watch this on-demand Webcast featuring expert perspective on therapeutic decision making and the latest evidence on treatment options for patients with advanced prostate cancer.

Pharmacists : 1.00 contact {hour} ({0.1} CEUs)

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Registered Nurses: 1.00 Nursing contact {hour}

Released: December 18, 2020

Expiration: December 17, 2021

No longer available for credit.

Share

Faculty

Robert Dreicer

Robert Dreicer, MD, MS, MACP, FASCO

Section Head, Medical Oncology
Associate Director for Clinical Research
Deputy Director
University of Virginia Cancer Center
Co-Director, Paul Mellon Urologic Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville,Virginia

Charles Ryan

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by the USF Health
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Sanofi Genzyme Corp

Target Audience

This program is intended for physicians, nurses, clinical pharmacists, and other healthcare providers who care for patients with advanced prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan optimal, individualized therapeutic strategies for patients with advanced or metastatic prostate cancer through exposure to expert insights and recommendations, real-world experience, and evidence-based and consensus-based guidelines
  • Evaluate new therapeutic options for nonmetastatic castration-resistant prostate cancer
  • Compare combinations of ADT with various agents vs ADT alone for metastatic hormone-sensitive prostate cancer
  • Apply expert recommendations for the sequencing of available and emerging hormonal, cytotoxic, immunologic, bone-directed, molecularly targeted, and other novel therapies (alone and in combination) to safely and effectively integrate them into the care of patients with metastatic castration-resistant prostate cancer
  • Assess and manage the risk for cardiotoxicity or bone loss prior to and/or during prostate cancer treatment
  • Refer appropriate patients with prostate cancer to ongoing clinical trials assessing novel therapies alone and in combination throughout the disease continuum to aid in trial enrollment

Faculty Disclosure

Primary Author

Robert Dreicer, MD, MS, MACP, FASCO

Section Head, Medical Oncology
Associate Director for Clinical Research
Deputy Director
University of Virginia Cancer Center
Co-Director, Paul Mellon Urologic Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville,Virginia

Robert Dreicer, MD, MS, MACP, FASCO has disclosed that he serves on advisory boards for Astellas, Bayer, Eisai, EMD Serono, Genentech, Myovant, Novartis, Pfizer, and Seattle Genetics.

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Charles J. Ryan, MD has disclosed that he serves on advisory boards for AAA, Bayer, Clovis, Myovant, and Roivant; he has research support from Clovis and Sanofi/Genzyme.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD has no relevant conflicts of interest to report.

Elizabeth O’Connell, PhD

Elizabeth O’Connell, PhD has no relevant conflicts of interest to report.

Kristi K. Orbaugh, MSN, RNP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physician
A Partner of MD Anderson
Indianapolis, Indiana

Kristi Orbaugh, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD has no relevant conflicts of interest to report.

Instructions for Credit

USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physician Continuing Medical Education

Credit Designation

USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 1.0 contact hour may be earned by learners who successfully complete this nursing continuing professional development activity.

USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 1.0 contact hour (0.1 CEU). Universal program number is as follows: 0230-9999-20-021-H01-P

Type of activity: Knowledge

For Pharmacists:
It is the responsibility of the pharmacy participant to ensure the provider has the learner’s birthday and e-Profile ID (ePID)/NABP number; it is the responsibility of the provider to submit to CPE Monitor participant information within 60 days of the activity for all participants who have attended, attested to their participation, and provided their ePID/NABP number and birthdate.

ACPE indicates it is the responsibility of the pharmacy professional to confirm the status of their NABP contact hours before 60 days past the activity. If there are any discrepancies, contact the provider immediately. You may contact USF Health through cpdsupport@usf.edu.

Disclosure of Unlabeled Use

USF Health OCPD staff have no relevant conflicts of interest to report.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 18, 2020, through December 17, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating recent findings into the treatment of patients with prostate cancer.